Biocon Chair: AI in Clinical Trials Is the Holy Grail

Biocon Executive Chairperson Kiran Mazumdar-Shaw said expiring biologic patents offer a runway to expand affordable cancer biosimilars and lift the company above its current top-five global ranking. Speaking at the Bloomberg New Economy Forum in New Delhi, she said AI accelerates molecular discovery, but the 'holy grail' is using it to shorten costly clinical trials by predicting safety and efficacy.